Immunic, Inc.

IMUX

US4525EP1011

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 11/06/2024 BST			5-day change	1st Jan Change
1.27 ^USD	+3.25%		+4.96%	-15.33%

05-08	Transcript : Immunic, Inc., Q1 2024 Earnings Call, May 08, 2024
05-08	Immunic, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Immunic, Inc. Appoints Tamar Howson to Its Board of Directors

October 15, 2019 at 11:30 am

Immunic, Inc. announced the appointment of Tamar Howson to its Board of Directors, effective October 11, 2019.

Latest news about Immunic, Inc.

Transcript : Immunic, Inc., Q1 2024 Earnings Call, May 08, 2024	05-08
Immunic, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-08	CI
Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & Neuroinflammation	04-30	CI
Transcript : Immunic, Inc. - Special Call	04-09
Immunic Gets US Patent Notice of Allowance For Specific Polymorph of Vidofludimus Calcium	03-21	MT
Wedbush Adjusts Immunic's PT to $4 From $7 on Increased Sharecount From First Tranche of Private Placemebt, Keeps Outperform Rating	02-23	MT
Transcript : Immunic, Inc., Q4 2023 Earnings Call, Feb 22, 2024	02-22
Immunic, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-22	CI
Immunic Launches 3-Tranche Private Placement of Up to $240 Million; Shares Rise	01-05	MT
Wall Street Set to Open Lower as Monthly Jobs Data Much Stronger Than Expected	01-05	MT
Investors Await Jobs Data as US Futures Trend Lower in Friday's Premarket	01-05	MT
Top Premarket Gainers	01-05	MT
Immunic Files $250 Million Mixed-Securities Shelf Registration	11-22	MT
Immunic Receives Notice of Allowance From US Patent Office for Dosing Regimens for Treating Multiple Sclerosis	11-21	MT
Transcript : Immunic, Inc., Q3 2023 Earnings Call, Nov 14, 2023	11-14
Immunic, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
North American Morning Briefing : Caution Dominates Ahead of CPI Print	11-14	DJ
Immunic, Inc. Receives Notice of Allowance for United States Patent Protecting the Treatment of Relapsing Multiple Sclerosis Vidofludimus and Its Salts	11-02	CI
Immunic Says Early-Stage Trial Shows 'Positive Effects' of Celiac Disease Drug Over Placebo	16/10/23	MT
Immunic, Inc. Presents Data From Phase 1b Clinical Trial of IMU-856 in Celiac Disease at the United European Gastroenterology Week 2023	15/10/23	CI
Wedbush Adjusts Price Target on Immunic to $7 From $5, Maintains Outperform Rating	10/10/23	MT
Transcript : Immunic, Inc. - Special Call	10/10/23
Top Premarket Gainers	10/10/23	MT
North American Morning Briefing: Treasury Yields Dive as Rate-Rise Fears Ease	10/10/23	DJ
Immunic Says Phase 2 Trial Reinforces Vidofludimus Calcium's Neuroprotective Potential; Shares Soar Premarket	10/10/23	MT

Immunic, Inc. is a biotechnology company. The Company is focused on developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. The Companyâs s lead development program, vidofludimus calcium (IMU-838), is in phase III and phase II clinical trials for the treatment of relapsing and progressive multiple sclerosis, respectively, and has shown therapeutic activity in phase II clinical trials in patients suffering from relapsing-remitting multiple sclerosis, progressive multiple sclerosis, and moderate-to-severe ulcerative colitis. IMU-856, which targets the protein Sirtuin 6 (SIRT6), is intended to restore intestinal barrier function and regenerate bowel epithelium, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease. IMU-381 is in preclinical testing, a next generation molecule being developed to specifically address the needs of gastrointestinal diseases.

Sector

Biotechnology & Medical Research

Calendar

06/11/2024 - Q3 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.27 USD

Average target price

11.5 USD

Spread / Average Target

+805.51%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
IMMUNIC, INC.	-15.33%	114M
VERTEX PHARMACEUTICALS INCORPORATED	+18.34%	124B
REGENERON PHARMACEUTICALS, INC.	+15.06%	109B
BIONTECH SE	-6.39%	23.84B
ARGENX SE	+1.16%	22.42B
GENMAB A/S	-14.90%	17.5B
WUXI APPTEC CO., LTD.	-41.64%	16.43B
BEIGENE, LTD.	-12.07%	16.61B
NEUROCRINE BIOSCIENCES, INC.	+1.05%	13.4B
SAREPTA THERAPEUTICS, INC.	+25.87%	11.47B

Bio Therapeutic Drugs

Immunic, Inc.

Equities

IMUX

US4525EP1011

Biotechnology & Medical Research

Immunic, Inc. Appoints Tamar Howson to Its Board of Directors

Latest news about Immunic, Inc.

Chart Immunic, Inc.

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs